Capecitabine
Capecitabine, sold under the brand name Xeloda among others, is a anticancer medication used to treat breast cancer, gastric cancer and colorectal cancer. For breast cancer it is often used together with docetaxel. It is taken by mouth.
Clinical data | |
---|---|
Pronunciation | /kæpɪˈsaɪtəbiːn/ |
Trade names | Xeloda, Xitabin, Kapetral, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a699003 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | chemotherapy agent |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Extensive |
Protein binding | < 60% |
Metabolism | liver, to 5'-DFCR, 5'-DFUR (inactive); neoplastic tissue, 5'-DFUR to active fluorouracil |
Elimination half-life | 38–45 minutes |
Excretion | kidney (95.5%), faecal (2.6%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.112.980 |
Chemical and physical data | |
Formula | C15H22FN3O6 |
Molar mass | 359.354 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
| |
(verify) |
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems such as cardiomyopathy, and low blood cell counts. Use during pregnancy may result in harm to the fetus. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-FU and tegafur.
Capecitabine was patented in 1992 and approved for medical use in 1998. It is on the World Health Organization's List of Essential Medicines.